The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value- adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
License agreement for Cebranopadol
Grünenthal exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership
Grünenthal announced the exclusive license agreement with Depomed, Inc. (DEPO), a California based specialty pharmaceutical company commercializing products for pain and neurology, on the development and commercialization of Cebranopadol for the U.S. and Canada. Cebranopadol is a novel, first in class, potent analgesic for chronic pain which has demonstrated its efficacy in multiple Phase II trials in moderate to severe chronic pain. Grünenthal and Depomed, Inc., applied a creative deal structure for this exclusive license agreement on Cebranopadol.